首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   216876篇
  免费   18550篇
  国内免费   13374篇
耳鼻咽喉   2005篇
儿科学   2910篇
妇产科学   4327篇
基础医学   25662篇
口腔科学   3806篇
临床医学   28732篇
内科学   34326篇
皮肤病学   2216篇
神经病学   11843篇
特种医学   7465篇
外国民族医学   107篇
外科学   22715篇
综合类   32194篇
现状与发展   40篇
一般理论   25篇
预防医学   13012篇
眼科学   6186篇
药学   22356篇
  165篇
中国医学   10408篇
肿瘤学   18300篇
  2024年   454篇
  2023年   2703篇
  2022年   6456篇
  2021年   9998篇
  2020年   7186篇
  2019年   6777篇
  2018年   7180篇
  2017年   6260篇
  2016年   5947篇
  2015年   9020篇
  2014年   11401篇
  2013年   10482篇
  2012年   15485篇
  2011年   17019篇
  2010年   10368篇
  2009年   8133篇
  2008年   11191篇
  2007年   11447篇
  2006年   11405篇
  2005年   11622篇
  2004年   7905篇
  2003年   7273篇
  2002年   6246篇
  2001年   5456篇
  2000年   5744篇
  1999年   5930篇
  1998年   3670篇
  1997年   3508篇
  1996年   2790篇
  1995年   2544篇
  1994年   2185篇
  1993年   1422篇
  1992年   2165篇
  1991年   1822篇
  1990年   1582篇
  1989年   1379篇
  1988年   1260篇
  1987年   1129篇
  1986年   896篇
  1985年   764篇
  1984年   448篇
  1983年   328篇
  1982年   201篇
  1981年   210篇
  1980年   155篇
  1979年   230篇
  1978年   112篇
  1977年   96篇
  1975年   99篇
  1974年   110篇
排序方式: 共有10000条查询结果,搜索用时 21 毫秒
21.
miRNAs是一类长度约为20~25个核苷酸,参与基因调控表达的内源性非编码RNA。miR-149作为miRNAs的重要成员,在多种肿瘤中表达异常,其表达水平与肿瘤细胞增殖、转移、凋亡、耐药、患者的早期诊断及预后密切相关。因此,miR-149有望成为新一类抗肿瘤治疗的靶点。  相似文献   
22.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
23.
24.
25.
26.
Bipolar disorder (BD) is a common psychiatric mood disorder affecting more than 1-2% of the general population of different European countries. Unfortunately, there is no objective laboratory-based test to aid BD diagnosis or monitor its progression, and little is known about the molecular basis of BD. Here, we performed a comparative proteomic study to identify differentially expressed plasma proteins in various BD mood states (depressed BD, manic BD, and euthymic BD) relative to healthy controls. A total of 10 euthymic BD, 20 depressed BD, 15 manic BD, and 20 demographically matched healthy control subjects were recruited. Seven high-abundance proteins were immunodepleted in plasma samples from the 4 experimental groups, which were then subjected to proteome-wide expression profiling by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight tandem mass spectrometry. Proteomic results were validated by immunoblotting and bioinformatically analyzed using MetaCore. From a total of 32 proteins identified with 1.5-fold changes in expression compared with healthy controls, 16 proteins were perturbed in BD independent of mood state, while 16 proteins were specifically associated with particular BD mood states. Two mood-independent differential proteins, apolipoprotein (Apo) A1 and Apo L1, suggest that BD pathophysiology may be associated with early perturbations in lipid metabolism. Moreover, down-regulation of one mood-dependent protein, carbonic anhydrase 1 (CA-1), suggests it may be involved in the pathophysiology of depressive episodes in BD. Thus, BD pathophysiology may be associated with early perturbations in lipid metabolism that are independent of mood state, while CA-1 may be involved in the pathophysiology of depressive episodes.  相似文献   
27.
28.
当代社会,老年人口比例呈现不断上升的趋势,老龄化问题日益严峻。因此,如何有效地延缓衰老不仅成为了世界医学研究的热点,也成为了全球亟待解决的问题。中医药在延缓衰老方面经验丰富,而滋阴药在此类研究中效果显著。本文通过整理滋阴药抗衰老作用机制的若干文献,对滋阴复方六味地黄丸、二至丸、左归丸及其他滋阴中药延缓衰老的机制研究进展进行综述。  相似文献   
29.
30.
Abstract

Objective

The sex, age, medical history, treatment, tobacco use, race risk (SAMe-TT2R2) Score; the sex, age, medical history, treatment, tobacco use, genotype combination (SAMe-TT2G2) Score; and the so-called modified SAMe-TT2R2 scores have been proposed to predict the anticoagulation quality for patients with non-valvular atrial fibrillation (NVAF). The data from a prospective controlled study is used to validate the SAMe-TT2R2 and SAMe-TT2G2 scores in Chinese NVAF patients treated with warfarin and to evaluate the association of factors with time in therapeutic range (TTR) to predict the quality of oral anticoagulation control.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号